Novocure Ltd. stock surges nearly 50% after positive late-stage trial results in brain cancer

MARKETWATCH | on Mon, Apr 3, 11:29 AM

Novocure Ltd. NVCR, +37.04%[1] shares surged 49.4% in morning trade Monday after the company said its late-stage clinical trial in newly diagnosed glioblastoma showed positive results. Novocure found that the two-year survival rate for patients improved from 30% to 43% after its drug Optune was added to standard temozolomide chemotherapy, and the five-year survival rate increased from 5% to 13%. Glioblastoma is a common type of brain cancer -- about 12,500 people are diagnosed with it in the ...

Read the full article

Semantic processing powered by OpenCalais

Use of the DailyMe service and DailyMe web site constitutes acceptance of the Company's Terms of Service and Privacy Policy.

© 2017 DailyMe, Inc. All rights reserved.